Literature DB >> 438546

Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis.

W T Siebert, N Moreland, T W Williams.   

Abstract

The in vitro activity of cephalothin, cefazolin, and vancomycin against 25 isolates of methicillin-resistant Staphylococcus epidermidis was determined by means of a broth dilution technique with two sizes of inoculum. The size of the inoculum had a marked effect on the minimal inhibitory concentrations and the minimal bactericidal concentrations of all three antibiotics. With a small inoculum, 100% of the isolates were inhibited by 3.12 micrograms of vancomycin/ml, 76% by 12.5 micrograms of cephalothin/ml, and 64% by 12.5 micrograms of cefazolin/ml. With a large inoculum 100% of the isolates were inhibited by 200 micrograms of vancomycin/ml, 40% by 12.5 micrograms of cephalothin/ml, and 12% by 12.5 micrograms of cefazolin/ml. As determined by a tube dilution checkerboard technique for both sizes of inoculum, the combination of vancomycin plus cephalothin was synergistic against methicillin-resistant S. epidermidis in 45 of 50 cases, and the combination of vancomycin plus cefazolin was synergistic in 39 or 50 cases. These data from in vitro studies suggest that these antibiotic combinations should be evaluated clinically in patients with severe infections caused by methicillin-resistant S. epidermidis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438546     DOI: 10.1093/infdis/139.4.452

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  A clinical view of vancomycin in 1990.

Authors:  W T Siebert
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 3.  Cephalosporins in gram-positive infections.

Authors:  J Symonds; A M Geddes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative Staphylococci isolated from orthopedic-device-associated infections.

Authors:  Julie Cremniter; Asma Slassi; Jean-Charles Quincampoix; Valérie Sivadon-Tardy; Thomas Bauer; Raphaël Porcher; Alain Lortat-Jacob; Philippe Piriou; Thierry Judet; Jean-Louis Herrmann; Jean-Louis Gaillard; Martin Rottman
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

Review 5.  Vancomycin resistance in staphylococci.

Authors:  Arjun Srinivasan; James D Dick; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

6.  Cross-resistance between methicillin and cephalosporins for staphylococci: a general assumption not true for cefamandole.

Authors:  R F Frongillo; P Bianchi; A Moretti; M B Pasticci; S Ripa; S Pauluzzi
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

7.  Comparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis.

Authors:  L J Wheat; J W Smith; J Reynolds; A T Bemis; T Treger; J A Norton
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

8.  Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis.

Authors:  M E Ein; N J Smith; J F Aruffo; M S Heerema; M W Bradshaw; T W Williams
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.